Informações de Johnson & Johnson

Mais detalhes de Johnson & Johnson Empresa

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).



Código da empresaJNJ

Nome da EmpresaJohnson & Johnson

Data de listagemSep 25, 1944

CEOMr. Joaquin Boix Duato

Número de funcionários138100

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 25

EndereçoOne Johnson & Johnson Plaza

CidadeNEW BRUNSWICK

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal08933

Telefone17325242455

Sitehttps://www.jnj.com/

Código da empresaJNJ

Data de listagemSep 25, 1944

CEOMr. Joaquin Boix Duato

Executivos da empresa Johnson & Johnson



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

--

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

--

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+14.54%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

--

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+18.96%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

14.12K

+20.79%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

12.85K

+17.90%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

10.66K

--

Mr. Hubert Joly

Independent Director

5.00K

--

Ms. Marillyn A. Hewson

Lead Independent Director

3.00K

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

276.91K

--

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

178.01K

--

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

94.62K

+14.54%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

84.95K

--

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.59K

+18.96%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

14.12K

+20.79%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Oncology-DARZALEX

3.54B

14.91%

Immunology-STELARA

1.65B

6.96%

Cardiovascular-ELECTROPHYSIOLOGY

1.47B

6.18%

Surgery-General

1.39B

5.86%

Immunology-TREMFYA

1.19B

5.00%

Outro

14.51B

61.10%

Por RegiãoUSD

Nome

Receita

Proporção

United States

13.54B

57.04%

Europe

5.39B

22.69%

Asia-Pacific, Africa

3.61B

15.19%

Western Hemisphere, excluding U.S.

1.21B

5.08%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Oncology-DARZALEX

3.54B

14.91%

Immunology-STELARA

1.65B

6.96%

Cardiovascular-ELECTROPHYSIOLOGY

1.47B

6.18%

Surgery-General

1.39B

5.86%

Immunology-TREMFYA

1.19B

5.00%

Outro

14.51B

61.10%

Distribuição de ações

Atualizado em: ter, 13 de mai

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.78%

State Street Investment Management (US)

5.51%

BlackRock Institutional Trust Company, N.A.

5.39%

Geode Capital Management, L.L.C.

2.52%

JP Morgan Asset Management

1.52%

Outro

75.29%

Investidores

Proporção

The Vanguard Group, Inc.

9.78%

State Street Investment Management (US)

5.51%

BlackRock Institutional Trust Company, N.A.

5.39%

Geode Capital Management, L.L.C.

2.52%

JP Morgan Asset Management

1.52%

Outro

75.29%

Tipos de investidores

Investidores

Proporção

Investment Advisor

38.83%

Investment Advisor/Hedge Fund

24.12%

Research Firm

3.00%

Pension Fund

2.38%

Bank and Trust

2.20%

Insurance Company

1.62%

Sovereign Wealth Fund

1.42%

Hedge Fund

0.69%

Family Office

0.09%

Outro

25.65%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

5871

1.79B

74.36%

+2.90M

2025Q2

5920

1.78B

73.89%

-7.65M

2025Q1

6002

1.80B

74.62%

+4.60M

2024Q4

5953

1.78B

74.14%

+8.28M

2024Q3

5699

1.77B

73.47%

+2.69M

2024Q2

5691

1.75B

72.75%

+9.12M

2024Q1

5685

1.73B

71.58%

-6.08M

2023Q4

5686

1.72B

71.40%

-7.80M

2023Q3

5524

1.72B

71.21%

-159.24M

2023Q2

5528

1.87B

71.81%

+6.27M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

236.03M

9.8%

+3.04M

+1.31%

Jun 30, 2025

State Street Investment Management (US)

132.80M

5.51%

-992.45K

-0.74%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

129.76M

5.39%

+619.12K

+0.48%

Jun 30, 2025

Geode Capital Management, L.L.C.

60.61M

2.52%

+1.23M

+2.06%

Jun 30, 2025

JP Morgan Asset Management

36.71M

1.52%

+1.46M

+4.13%

Jun 30, 2025

State Farm Insurance Companies

34.37M

1.43%

--

Jun 30, 2025

Norges Bank Investment Management (NBIM)

31.93M

1.33%

+1.57M

+5.18%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

25.30M

1.05%

+1.23M

+5.13%

Jun 30, 2025

Wellington Management Company, LLP

24.88M

1.03%

+2.23M

+9.85%

Jun 30, 2025

BlackRock Asset Management Ireland Limited

19.85M

0.82%

+148.42K

+0.75%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

iShares U.S. Pharmaceuticals ETF

23.26%

iShares ESG Aware MSCI USA Value ETF

12.37%

Health Care Select Sector SPDR Fund

8.85%

Proshares Ultra Health Care

8.83%

iShares U.S. Healthcare ETF

8.5%

FT Vest DJIA Dogs 10 Target Income ETF

8.21%

JPMorgan Healthcare Leaders ETF

7.97%

Fidelity MSCI Health Care Index ETF

7.7%

Franklin Income Focus ETF

7.69%

First Trust NASDAQ Pharmaceuticals ETF

7.68%

Ver Mais

iShares U.S. Pharmaceuticals ETF

Proporção23.26%

iShares ESG Aware MSCI USA Value ETF

Proporção12.37%

Health Care Select Sector SPDR Fund

Proporção8.85%

Proshares Ultra Health Care

Proporção8.83%

iShares U.S. Healthcare ETF

Proporção8.5%

FT Vest DJIA Dogs 10 Target Income ETF

Proporção8.21%

JPMorgan Healthcare Leaders ETF

Proporção7.97%

Fidelity MSCI Health Care Index ETF

Proporção7.7%

Franklin Income Focus ETF

Proporção7.69%

First Trust NASDAQ Pharmaceuticals ETF

Proporção7.68%

Dividendo



Um total de 56.79B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Jan 02, 2025

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025

Feb 18, 2025

Mar 04, 2025

Feb 18, 2025

Oct 15, 2024

JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024

Nov 26, 2024

Dec 10, 2024

Nov 26, 2024

Jul 17, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024

Aug 27, 2024

Sep 10, 2024

Aug 27, 2024

Apr 16, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024

May 21, 2024

Jun 04, 2024

May 20, 2024

Jan 02, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024

Feb 20, 2024

Mar 05, 2024

Feb 16, 2024

Oct 19, 2023

JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023

Nov 21, 2023

Dec 05, 2023

Nov 20, 2023

Jul 20, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023

Aug 28, 2023

Sep 07, 2023

Aug 25, 2023

Apr 18, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023

May 23, 2023

Jun 06, 2023

May 22, 2023

Jan 03, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023

Feb 21, 2023

Mar 07, 2023

Feb 17, 2023

Oct 18, 2022

JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022

Nov 22, 2022

Dec 06, 2022

Nov 21, 2022

Ver Mais

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados